Open AccessIDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes
Author(s) -
Na Wang,
Fei Wang,
Ningning Shan,
Xiaohui Sui,
Hongzhi Xu
Publication year - 2017
Publication title -
acta haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 56
eISSN - 1421-9662
pISSN - 0001-5792
DOI - 10.1159/000479546
Subject(s) - idh2 , idh1 , isocitrate dehydrogenase , hazard ratio , medicine , myelodysplastic syndromes , mutation , oncology , international prognostic scoring system , gastroenterology , biology , confidence interval , bone marrow , genetics , gene , biochemistry , enzyme
Genomic sequencing technologies have identified isocitrate dehydrogenase (IDH) mutations in haematological malignancies. The prognostic implications of somatic IDH mutation (mIDH) in myelodysplastic syndromes (MDS) remain controversial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom